Metastatic Survey Results

In late 2023, Pheo Para Alliance launched a survey to gather information to develop a strategy to best support metastatic patients following the announcement regarding the cease of production of Azedra, the only FDA approved treatment for metastatic and unresectable pheo & para.  Fifty three clinicians from twenty-eight centers participated globally.

This survey was created as part of the Advocacy Committee.

View the results of the survey here.